Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

(Reuters) -Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

Eli Lilly (NYSE: LLY) has entered into a collaboration with Boston-based Superluminal Medicines to develop small-molecule ...

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...

Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for GPCR ...

Eli Lilly (LLY) recently collaborated with Superluminal Medicines to advance therapeutics targeting cardiometabolic diseases, ...

The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new ...

Yahoo Finance anchor Julie Hyman tracks Thursday's top stocks and market movers in this Market Minute. C3.ai (AI) stock dips ...

In a move poised to shake the pharmaceutical landscape, Eli Lilly & Co. has inked a deal worth up to $1.3 billion with ...

Eli Lilly has signed a deal worth up to $1.3 billion with privately held Superluminal Medicines to discover and develop drugs ...

Superluminal Medicines said on Thursday it had signed a deal with U.S. drugmaker Eli Lilly worth up to $1.3 billion to ...